Santacruz Escudero José Manuel, Beltrán Jonathan, Palacios Álvaro, Chimbí Claudia Marcela, Matallana Diana, Reyes Pablo, Perez-Sola Victor, Santamaría-García Hernando
Departments of Psychiatry, Physiology and Institute for Studies on the Aging, Pontificia Universidad Javeriana, Bogotá, Colombia.
Intellectus Memory and Cognition Center, Hospital Universitario San Ignacio, Bogotá, Colombia.
Front Aging Neurosci. 2019 Jul 24;11:176. doi: 10.3389/fnagi.2019.00176. eCollection 2019.
: To study the extent to which neuropsychiatric symptoms (NPS) influence the cognitive and functional decline in frontotemporal degeneration (FTD) and Alzheimer's disease (AD). : We assessed the progression of NPS and their influence on cognitive and functional progression in a group of FTD ( = 36) and AD patients ( = 47) at two different stages of the disease (2.5 years). A standardized scale was used to assess NPS-the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD)-which tracks different symptoms including depression, psychotic symptoms, as well as sleep and conduct problems. In addition, in a subsample of patients (AD = 14 and FTD = 14), we analyzed another group of NPS by using the Neuropsychiatric Inventory (NPI). Cognitive declines were tracked by using the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), while functionality was tracked by using the Lawton scale and the Barthel Index. : The presence of NPS impacts cognitive and functional decline in both groups of patients 2.5 years after disease onset. However, we observed a dissociable profile of the affectation of NPS in each group. In the AD group, results indicate that the progression of depressive symptoms and sleep problems predict cognitive and functional decline. In contrast, the progression of a mixed group of NPS, including conduct problems and delusions, predicts cognitive and functional decline in FTD. : The presence of NPS has a critical impact on the prediction of cognitive decline in FTD and AD patients after 2.5 years of disease progression. Our results demonstrate the importance of assessing different types of NPS in neurodegenerative disorders which, in turn, predict disease progression. Future studies should assess the role of NPS in predicting different neurocognitive pathways and in neurodegeneration.
研究神经精神症状(NPS)对额颞叶变性(FTD)和阿尔茨海默病(AD)认知及功能衰退的影响程度。我们评估了一组FTD患者(n = 36)和AD患者(n = 47)在疾病的两个不同阶段(2.5年)NPS的进展情况及其对认知和功能进展的影响。使用标准化量表——哥伦比亚大学阿尔茨海默病精神病理学量表(CUSPAD)来评估NPS,该量表可追踪不同症状,包括抑郁、精神症状以及睡眠和行为问题。此外,在患者的一个子样本中(AD患者n = 14,FTD患者n = 14),我们使用神经精神科问卷(NPI)分析了另一组NPS。使用蒙特利尔认知评估量表(MoCA)和简易精神状态检查表(MMSE)追踪认知衰退情况,同时使用洛顿量表和巴氏指数追踪功能情况。疾病发作2.5年后,NPS的存在对两组患者的认知和功能衰退均有影响。然而,我们观察到每组中NPS影响情况的可分离特征。在AD组中,结果表明抑郁症状和睡眠问题的进展可预测认知和功能衰退。相比之下,包括行为问题和妄想在内的一组混合NPS的进展可预测FTD患者的认知和功能衰退。疾病进展2.5年后,NPS的存在对FTD和AD患者认知衰退的预测具有关键影响。我们的结果证明了在神经退行性疾病中评估不同类型NPS的重要性,而这反过来又可预测疾病进展。未来的研究应评估NPS在预测不同神经认知途径和神经退行性变中的作用。